Hubert Maehr Selected Research

1,25- dihydroxy- 21- (3- hydroxy- 3- methyl- 4,4,4- tributyl)- 23- yne- 26,27- hexafluorocholecalciferol

1/2020	Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds.
10/2017	Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.
10/2017	Structural analysis and biological activities of BXL0124, a gemini analog of vitamin D.
4/2015	Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.
4/2015	HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
6/2014	Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
9/2013	Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.
1/2013	Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer.
3/2011	A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer.
7/2010	Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hubert Maehr Research Topics

Disease

14	Breast Neoplasms (Breast Cancer) 01/2020 - 07/2006
13	Neoplasms (Cancer) 01/2020 - 03/2007
7	Carcinogenesis 01/2020 - 07/2006
4	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020 - 06/2014
4	Neoplasm Metastasis (Metastasis) 01/2020 - 03/2011
2	Hypercalcemia (Milk Alkali Syndrome) 11/2008 - 01/2006
1	Breast Ductal Carcinoma 01/2020
1	Triple Negative Breast Neoplasms 10/2017
1	Ductal Carcinoma 06/2014
1	Body Weight (Weight, Body) 03/2011
1	Leukemia 07/2007
1	Colonic Neoplasms (Colon Cancer) 03/2007

Drug/Important Bio-Agent (IBA)

11	Vitamin D FDA LinkGeneric 01/2020 - 07/2006
10	1,25- dihydroxy- 21- (3- hydroxy- 3- methyl- 4,4,4- tributyl)- 23- yne- 26,27- hexafluorocholecalciferolIBA 01/2020 - 07/2010
5	Cholecalciferol (Vitamin D3)FDA Link 01/2013 - 01/2006
3	hydroxide ionIBA 01/2020 - 04/2015
3	Calcitriol (Calcijex)FDA LinkGeneric 07/2007 - 01/2006
2	Proteins (Proteins, Gene)FDA Link 01/2013 - 03/2011
2	Estrogen ReceptorsIBA 07/2010 - 11/2008
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Keratin-5 (Keratin 5)IBA 10/2017
1	Biomarkers (Surrogate Marker)IBA 10/2017
1	Calcitriol Receptors (Calcitriol Receptor)IBA 06/2014
1	KalininIBA 06/2014
1	ErbB Receptors (EGF Receptor)IBA 09/2013
1	1- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazoleIBA 09/2013
1	Phosphotransferases (Kinase)IBA 09/2013
1	TriterpenesIBA 09/2013
1	Tyrosine (L-Tyrosine)FDA Link 09/2013
1	Peptides (Polypeptides)IBA 05/2013
1	LigandsIBA 05/2013
1	Glycoproteins (Glycoprotein)IBA 01/2013
1	CalciumIBA 03/2011
1	CarcinogensIBA 07/2010
1	Insulin-Like Growth Factor Binding Protein 3IBA 11/2008
1	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 11/2008
1	1,25-dihydroxyvitamin DIBA 11/2008
1	Cyclin-Dependent Kinase Inhibitor p21IBA 11/2008
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 12/2007
1	Transforming Growth Factor beta (TGF-beta)IBA 12/2007
1	ReninIBA 03/2007
1	Messenger RNA (mRNA)IBA 03/2007
1	Ro43 83582IBA 07/2006
1	Interferon-gamma (Interferon, gamma)IBA 01/2006
1	cyclopropaneIBA 01/2006

Therapy/Procedure

3	Therapeutics 10/2017 - 03/2011
1	Chemoprevention 01/2020
1	Treatment Delay 09/2013
1	Oral Administration 09/2013